Speciality: Dermatology
Description:
A warm welcome to all the medical professionals in this interesting session on the current treatment paradigm for Atopic Dermatitis, the role of PDE4 in AD, and the mechanism of action Crisaborole.
The current treatment paradigm for Atopic Dermatitis (AD) emphasizes a multifaceted approach targeting inflammation and itch relief. Topical corticosteroids and calcineurin inhibitors are frontline treatments, while systemic therapies may be considered for severe cases. Additionally, emerging biologic agents targeting specific immune pathways offer promising options for refractory AD.
Phosphodiesterase-4 (PDE4) inhibitors, like Crisaborole, have gained attention for their role in AD management. PDE4 regulates inflammatory responses by degrading cyclic adenosine monophosphate (cAMP), thereby modulating cytokine production. In AD, elevated levels of pro-inflammatory cytokines contribute to skin inflammation and barrier dysfunction. By inhibiting PDE4, Crisaborole reduces inflammation and restores skin barrier function, offering a targeted approach to AD treatment with favorable safety and efficacy profiles.
Therefore, get an overall knowledge of the current treatment paradigm for Atopic Dermatitis, the role of PDE4 in AD, and the mechanism of action Crisaborole. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.
2.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
3.
Racial differences seen in epigenetic age acceleration in childhood cancer survivors
4.
ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer
5.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
1.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
2.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
3.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
How to Prevent Tumor Lysis Syndrome in Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Navigating the Complexities of Ph Negative ALL - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation